Upexi (UPXI) Competitors

$1.45 -0.07 (-4.61%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$1.39 -0.06 (-4.07%)

As of 05/15/2026 07:58 PM Eastern

UPXI vs. PBYI, SRZN, CCCC, NMRA, and GLSI

Should you buy Upexi stock or one of its competitors? MarketBeat compares Upexi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Upexi include Puma Biotechnology (PBYI), Surrozen (SRZN), C4 Therapeutics (CCCC), Neumora Therapeutics (NMRA), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry.

How does Upexi compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Upexi has a consensus price target of $8.33, suggesting a potential upside of 474.71%. Given Upexi's stronger consensus rating and higher possible upside, analysts plainly believe Upexi is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Puma Biotechnology has a net margin of 10.69% compared to Upexi's net margin of -874.00%. Puma Biotechnology's return on equity of 20.30% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Upexi	-874.00%	-66.70%	-19.56%

Puma Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Upexi has a beta of -0.32, suggesting that its stock price is 132% less volatile than the broader market.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 9.0% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Puma Biotechnology has higher revenue and earnings than Upexi. Upexi is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.54	$31.11M	$0.48	14.42
Upexi	$26.14M	3.90	-$13.68M	-$3.23	N/A

In the previous week, Upexi had 7 more articles in the media than Puma Biotechnology. MarketBeat recorded 12 mentions for Upexi and 5 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.52 beat Upexi's score of -0.05 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upexi	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Puma Biotechnology beats Upexi on 11 of the 17 factors compared between the two stocks.

How does Upexi compare to Surrozen?

Surrozen (NASDAQ:SRZN) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Upexi has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	43.61	-$242.03M	-$37.59	N/A
Upexi	$26.14M	3.90	-$13.68M	-$3.23	N/A

In the previous week, Upexi had 4 more articles in the media than Surrozen. MarketBeat recorded 12 mentions for Upexi and 8 mentions for Surrozen. Surrozen's average media sentiment score of 0.10 beat Upexi's score of -0.05 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upexi	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

66.6% of Surrozen shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 9.0% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Surrozen presently has a consensus price target of $42.00, suggesting a potential upside of 49.20%. Upexi has a consensus price target of $8.33, suggesting a potential upside of 474.71%. Given Upexi's higher probable upside, analysts clearly believe Upexi is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Surrozen has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Upexi has a beta of -0.32, meaning that its share price is 132% less volatile than the broader market.

Upexi has a net margin of -874.00% compared to Surrozen's net margin of -4,810.50%. Upexi's return on equity of -66.70% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
Upexi	-874.00%	-66.70%	-19.56%

Summary

Upexi beats Surrozen on 9 of the 16 factors compared between the two stocks.

How does Upexi compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

In the previous week, C4 Therapeutics had 1 more articles in the media than Upexi. MarketBeat recorded 13 mentions for C4 Therapeutics and 12 mentions for Upexi. C4 Therapeutics' average media sentiment score of 0.46 beat Upexi's score of -0.05 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upexi	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Upexi has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	10.95	-$104.99M	-$1.19	N/A
Upexi	$26.14M	3.90	-$13.68M	-$3.23	N/A

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 9.0% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

C4 Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the broader market. Comparatively, Upexi has a beta of -0.32, meaning that its share price is 132% less volatile than the broader market.

C4 Therapeutics presently has a consensus price target of $7.75, suggesting a potential upside of 117.70%. Upexi has a consensus price target of $8.33, suggesting a potential upside of 474.71%. Given Upexi's stronger consensus rating and higher probable upside, analysts clearly believe Upexi is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

C4 Therapeutics has a net margin of -297.76% compared to Upexi's net margin of -874.00%. C4 Therapeutics' return on equity of -50.68% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Upexi	-874.00%	-66.70%	-19.56%

Summary

C4 Therapeutics beats Upexi on 10 of the 17 factors compared between the two stocks.

How does Upexi compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Upexi had 10 more articles in the media than Neumora Therapeutics. MarketBeat recorded 12 mentions for Upexi and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.94 beat Upexi's score of -0.05 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upexi	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Upexi has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Upexi	$26.14M	3.90	-$13.68M	-$3.23	N/A

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 9.0% of Upexi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Neumora Therapeutics has a beta of 3.02, meaning that its stock price is 202% more volatile than the broader market. Comparatively, Upexi has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market.

Neumora Therapeutics presently has a consensus price target of $7.67, suggesting a potential upside of 316.67%. Upexi has a consensus price target of $8.33, suggesting a potential upside of 474.71%. Given Upexi's stronger consensus rating and higher possible upside, analysts clearly believe Upexi is more favorable than Neumora Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Neumora Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Upexi	-874.00%	-66.70%	-19.56%

Summary

Upexi beats Neumora Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Upexi compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Greenwich LifeSciences presently has a consensus target price of $47.50, indicating a potential upside of 74.57%. Upexi has a consensus target price of $8.33, indicating a potential upside of 474.71%. Given Upexi's stronger consensus rating and higher probable upside, analysts plainly believe Upexi is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Upexi has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
Upexi	$26.14M	3.90	-$13.68M	-$3.23	N/A

Greenwich LifeSciences has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Upexi has a beta of -0.32, indicating that its stock price is 132% less volatile than the broader market.

Greenwich LifeSciences has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
Upexi	-874.00%	-66.70%	-19.56%

In the previous week, Upexi had 11 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 12 mentions for Upexi and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.62 beat Upexi's score of -0.05 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Greenwich LifeSciences	Positive
Upexi	Neutral

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 9.0% of Upexi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Upexi beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks.

Get Upexi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPXI vs. The Competition

Export

Metric	Upexi	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$106.80M	$3.92B	$6.41B	$12.48B
Dividend Yield	N/A	2.16%	3.18%	5.25%
P/E Ratio	-0.45	53.21	31.07	25.24
Price / Sales	3.90	47.02	417.72	82.25
Price / Cash	N/A	40.21	23.29	56.04
Price / Book	-1.96	5.36	6.75	6.90
Net Income	-$13.68M	$32.30M	$203.22M	$334.66M
7 Day Performance	5.07%	8.21%	1.82%	0.13%
1 Month Performance	11.54%	-3.85%	-3.01%	1.11%
1 Year Performance	-85.77%	27.19%	31.11%	30.62%

Upexi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPXI Upexi	1.6651 of 5 stars	$1.45 -4.6%	$8.33 +474.7%	-84.9%	$106.80M	$26.14M	N/A	130	News Coverage Earnings Report Gap Down
PBYI Puma Biotechnology	1.4309 of 5 stars	$6.97 -2.5%	N/A	+111.0%	$354.52M	$228.40M	14.51	200	Positive News
SRZN Surrozen	3.4457 of 5 stars	$30.77 +5.1%	$42.00 +36.5%	+310.9%	$353.55M	$3.48M	N/A	80	News Coverage Gap Down
CCCC C4 Therapeutics	1.8543 of 5 stars	$3.17 -0.1%	$7.75 +144.8%	+158.0%	$348.83M	$35.95M	N/A	150	Trending News Earnings Report Analyst Revision
NMRA Neumora Therapeutics	3.5762 of 5 stars	$1.89 +1.2%	$7.67 +305.2%	+176.4%	$345.65M	N/A	N/A	108	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPXI) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upexi (UPXI) Competitors

UPXI vs. PBYI, SRZN, CCCC, NMRA, and GLSI

How does Upexi compare to Puma Biotechnology?

Summary

How does Upexi compare to Surrozen?

Summary

How does Upexi compare to C4 Therapeutics?

Summary

How does Upexi compare to Neumora Therapeutics?

Summary

How does Upexi compare to Greenwich LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI vs. The Competition

Upexi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upexi (UPXI) Competitors

UPXI vs. PBYI, SRZN, CCCC, NMRA, and GLSI

How does Upexi compare to Puma Biotechnology?

Do analysts rate PBYI or UPXI?

Is PBYI or UPXI more profitable?

Which has more volatility and risk, PBYI or UPXI?

Do insiders & institutionals have more ownership in PBYI or UPXI?

Which has higher valuation & earnings, PBYI or UPXI?

Does the media refer more to PBYI or UPXI?

Summary

How does Upexi compare to Surrozen?

Which has stronger valuation and earnings, SRZN or UPXI?

Does the media refer more to SRZN or UPXI?

Do institutionals & insiders hold more shares of SRZN or UPXI?

Do analysts recommend SRZN or UPXI?

Which has more risk and volatility, SRZN or UPXI?

Is SRZN or UPXI more profitable?

Summary

How does Upexi compare to C4 Therapeutics?

Does the media refer more to CCCC or UPXI?

Which has stronger valuation and earnings, CCCC or UPXI?

Do institutionals & insiders hold more shares of CCCC or UPXI?

Which has more risk and volatility, CCCC or UPXI?

Do analysts recommend CCCC or UPXI?

Is CCCC or UPXI more profitable?

Summary

How does Upexi compare to Neumora Therapeutics?

Does the media prefer NMRA or UPXI?

Which has higher earnings and valuation, NMRA or UPXI?

Do institutionals & insiders hold more shares of NMRA or UPXI?

Which has more volatility & risk, NMRA or UPXI?

Do analysts recommend NMRA or UPXI?

Is NMRA or UPXI more profitable?

Summary

How does Upexi compare to Greenwich LifeSciences?

Do analysts recommend GLSI or UPXI?

Which has higher earnings and valuation, GLSI or UPXI?

Which has more volatility and risk, GLSI or UPXI?

Is GLSI or UPXI more profitable?

Does the media refer more to GLSI or UPXI?

Do insiders & institutionals have more ownership in GLSI or UPXI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI vs. The Competition

Upexi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools